Communications Equipment

Network 1 Tech

Network 1 Tech released FY2026 Q1 earnings on May 8 (EST), actual revenue USD 0, actual EPS USD -0.0223

Network 1 Tech released FY2025 Q4 earnings on March 13 (EST), actual revenue USD 0, actual EPS USD -0.05

Network 1 Tech released FY2025 earnings on March 13 (EST), actual revenue USD 150K, actual EPS USD -0.1099

Network 1 Tech released FY2025 Q3 earnings on November 6, 2025 (EST) with actual revenue of USD 0 and EPS of USD -0.0245

Network 1 Tech released FY2025 9 Months Earnings on November 6 (EST), with actual revenue of USD 150K and EPS of USD -0.0647

Network 1 Tech released FY2025 Q2 earnings on August 8 (EST) with actual revenue of USD 0 and EPS of USD -0.0202

Network 1 Tech released FY2025 Semi-Annual Earnings on August 8, 2025 (EST) with actual revenue of USD 150 K and EPS of USD -0.0399

Network 1 Tech released FY2025 Q1 earnings on May 9 (EST), actual revenue USD 150 K, actual EPS USD -0.02

Network-1 Technologies Acquires Patent Portfolio Related to Advanced Security Technologies

Network 1 Tech released FY2024 Q4 earnings on February 28 (EST) with actual revenue of 0 USD and EPS of -0.0502 USD

Network 1 Tech released FY2024 Annual Earnings on February 28 (EST), with actual revenue of 100 K USD and EPS of -0.1304 USD

Network 1 Tech released FY2024 Q3 earnings on October 24, 2024 (EST) with actual revenue of 0 and EPS of -0.0136

Network-1 Technologies, Inc. released Q3 2024 earnings on October 24, 2024, with EPS -0.0836 and revenue $100,000

OPTIMI HEALTH CORP

HCW Biologics

FLAG SHIP ACQUISITION CORPORATION COM USD0.001 (SUB/RIGHT 31/03/2026)

Micware

GCL Global

Silexion Therapeutics

MicroAlgo

MetaVia

BiomX

Vida Global

NTIP

Earnings Watch

Network 1 Tech | 8-K: FY2026 Q1 Revenue: USD 0

Network 1 Tech | 10-Q: FY2026 Q1 Revenue: USD 0

Network 1 Reports First Quarter 2026 Financial Results | NTIP Stock News

StockTitan

Network 1 Reports First Quarter 2026 Financial Results | NTIP Stock News

Network-1 Technologies (NTIP) won a key appeal in its patent dispute with Google, as the U.S. Court of Appeals overturned a previous non-infringement ruling regarding its U.S. Patent No. 8,205,237. The case will proceed to jury trial, potentially impacting Network-1 financially after years of litigation. While some claims in other patents were deemed invalid, the core infringement theory on the ’237 patent remains intact. Spark's analysis rates NTIP as Neutral due to weak financial performance but notes a strong balance sheet and positive technical momentum. Network-1 focuses on monetizing various patent portfolios.

Tip Ranks

Alphabet

Alphabet - C

Network-1 Wins Key Appeal in Google Patent Dispute

The Federal Circuit has reversed a non-infringement ruling for Network-1 Technologies' Patent No. 8,205,237, remanding the case for further proceedings. The court upheld the invalidity of certain claims in other patents and confirmed that a prior Content ID implementation did not infringe the ’237 patent. This ruling is significant for Network-1's ongoing litigation against Google and YouTube, potentially leading to substantial damages if infringement is proven.

TradingView

Federal Circuit reverses non-infringement for Network-1’s ’237 patent, remands infringement for further proceedings

NTLA

CTNT

SCNI

POET

In the past hour, the overall market in the US stock market has shown significant differentiation, with technology stocks and the biopharmaceutical sector performing particularly well. The strong rise of Intellia Therapeutics has attracted market attention, driving the activity of related biotech stocks. Meanwhile, Cheetah Net Supply Chain and Scinai Immunotherapeutics have experienced significant declines, indicating a rapid shift of funds between different sectors. Short-term interest seems to be concentrated on those promising technology and pharmaceutical stocks, with large fluctuations and active market sentiment. The stock with the largest movement in the past hour, Intellia Therapeutics, surged by 31.33%, becoming the market focus. The strong performance of this stock has attracted a large influx of funds, boosting short-term sentiment and driving the overall rise of the biotech sector. Strong stocks include: 1. Organon: up 16.61%, with recent market attention on its product line and noticeable fund inflow. 2. MagnaChip Semiconductor: up 16.38%, benefiting from the recovery in semiconductor demand, with short-term funds actively participating. 3. SurgePays: up 7.70%, as the company's recent financial report exceeded expectations, attracting investor interest. 4. POET Tech: up 7.62%, with optimistic market expectations regarding its technological progress driving the stock price increase

- The U.S. stock market exhibited significant divergence, with notable performances in the technology and biotechnology sectors, particularly driven by Intellia Therapeutics, which rose by 31.33%.  
- Meanwhile, Cheetah Net Supply Chain and Scinai Immunotherapeutics faced declines of 20.00% and 19.17%, respectively, indicating rapid capital shifts among sectors.  
- Strong gains were also recorded in companies like Organon and MagnaChip Semiconductor, reflecting heightened investor interest in tech and healthcare stocks amid active market sentiment.

Price Alert

Intellia Therap

Cheetah Net Supply Chain

Scinai Immunotherapeutics

Organon

Magnachip Semiconduct

Zspace

SurgePays

POET Tech

XORTX Therapeutics

Maxlinear

Faraday Future Intelligent Electric

Wing Yip Food China

Qualcomm

Wheeler Real Estate

U.S. Stock Market Movement Update: The biotechnology sector rebounded strongly, with Intellia rising 31.33% to lead the gains, while Cheetah fell 20%, attracting attention

In the past hour, the overall market in the U.S. stock market has shown significant differentiation, with technology stocks and the biopharmaceutical sector performing strongly, attracting a large influx of capital. In particular, the strong rise of Intellia Therap has seemingly ignited investor enthusiasm for biotechnology, driving the activity of related stocks. Meanwhile, Cheetah Net Supply Chain and Scinai Immunotherapeutics have encountered significant declines, reflecting a polarization of market sentiment. Short-term enthusiasm has notably increased in the technology and pharmaceutical sectors, with heightened volatility and a clear preference for high-growth stocks. The stock with the largest movement in the past hour, Intellia Therap, surged by 30.59%, becoming the market's focal point. The stock quickly rallied after the opening, attracting a large amount of short-term capital, with sentiment running high, seemingly indicating optimistic expectations for its future prospects. Strong stocks include: 1. Organon: up 16.52%, with recent market attention on its product line and noticeable capital inflow. 2. MagnaChip Semiconduct: up 14.67%, benefiting from a recovery in semiconductor demand, with short-term capital actively participating. 3. Hesai: up 8.46%, with ongoing innovations in the intelligent driving field sparking investor enthusiasm. 4. SurgePays: up 7.70%, with the company's new developments in payment solutions attracting market attention

- The U.S. stock market recently showed significant divergence, with technology and biotech sectors attracting substantial investment, particularly highlighted by a 30.59% surge in Intellia Therapeutics.  
- Strong performers included Organon, MagnaChip Semiconductor, and others, benefiting from renewed interest and demand in their respective areas.  
- Conversely, Cheetah Net Supply Chain and Scinai Immunotherapeutics faced considerable declines, reflecting polarized market sentiment amid concerns over supply chain management and R&D progress.

Hesai

System1

U.S. Stock Market Movement Update: Healthcare stocks rebound strongly, Intellia rises over 30%, Cheetah drops 20%

POET Tech rose 10.53% in after-hours trading; Network 1 Tech fell 8.84% in after-hours trading; Intellia Therapeutics rose 27.73% in after-hours trading; Organon rose 21.05% in after-hours trading; Brown-Forman rose 14.50% in after-hours trading

U.S. stock night trading opens with fluctuations: POET Tech rises 10.53% in night trading; Network 1 Tech falls 8.84% in night trading

Network 1 Technologies (NTIP.US) is currently priced at $1.335, down 8.56% for the day, with an intraday decline exceeding 8%, triggering a 5-minute drop warning. The patent licensing company Network 1 previously surged over 10% after the Federal Circuit Court overturned a lower court ruling, determining that its patent claims were victorious. This recent pullback is a short-term profit-taking after the market digested the positive news. Although the outcome of the patent litigation supports the company's licensing revenue, the victory bonus has already been largely reflected in the previous price increase, leading to a retreat in short-term buying pressure and a subsequent price correction

Movers Alert

Network 1 Technologies Drops Over 8% as Post-Ruling Rally Reverses

Network 1 Tech(NTIP.US)

Network 1 Tech | 8-K: FY2026 Q1 Revenue: USD 0

Network 1 Tech | 10-Q: FY2026 Q1 Revenue: USD 0

Network 1 Reports First Quarter 2026 Financial Results | NTIP Stock News

Network-1 Wins Key Appeal in Google Patent Dispute

Federal Circuit reverses non-infringement for Network-1’s ’237 patent, remands infringement for further proceedings

U.S. Stock Market Movement Update: The biotechnology sector rebounded strongly, with Intellia rising 31.33% to lead the gains, while Cheetah fell 20%, attracting attention

U.S. Stock Market Movement Update: Healthcare stocks rebound strongly, Intellia rises over 30%, Cheetah drops 20%

U.S. stock night trading opens with fluctuations: POET Tech rises 10.53% in night trading; Network 1 Tech falls 8.84% in night trading

Network 1 Technologies Drops Over 8% as Post-Ruling Rally Reverses